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Abstract 
 
Von Hippel-Lindau syndrome (VHLS) is a rare hereditary neoplastic disorder caused by 
mutations in the vhl gene leading to the development of tumors in several organs including 
the central nervous system, pancreas, kidneys, and reproductive organs. Manifestations of 
VHLS can present at different ages based on the affected organ and subclass of disease. In 
the subclasses of VHLS that cause renal disease, renal involvement typically begins closer to 
the end of the second decade of life and can present in different ways ranging from simple 
cystic lesions to solid tumors. Mutations in vhl are most often associated with clear cell renal 
carcinoma, the most common type of renal cancer, and also play a major role in sporadic 
cases of clear cell renal carcinoma. The recurrent, multifocal nature of this disease presents 
difficult challenges in the long-term management of patients with VHLS. Optimization of renal 
function warrants the use of several different approaches common to the management of 
renal carcinoma such as nephron sparing surgery, enucleation, ablation, and targeted 
therapies. In VHLS, renal lesions of 3 cm or bigger are considered to have metastatic potential 
and even small lesions often harbor malignancy. Many of the aspects of management revolve 
around optimizing both oncologic outcome and long-term renal function. As new surgical 
strategies and targeted therapies develop, the management of this complex disease evolves.  
This review will discuss the key aspects of the current management of VHLS.  
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Introduction 
 
Von Hippel-Lindau syndrome (VHLS) is a 
rare, but highly penetrant, autosomal 
dominant hereditary neoplastic disorder 
caused by a genetic mutation in the vhl gene 
(vhl) that occurs in roughly 1 in 36,000 
births (1). Mutations in vhl can be deletions 
or missense in the short arm of chromosome 
3, resulting in an increased propensity to 
develop a variety of benign and malignant 
tumors, such as hemangioblastomas in the 
central nervous system (CNS), renal cysts 
and renal cell carcinomas (RCC), 
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pheochromocytomas, pancreatic islet cell 
tumors, endolymphatic sac tumors, and 
both broad ligament and epididymal 
cystadenomas in women and men, 
respectively (1, 2). The disease is classified 
into type 1, the result of a nonsense 
mutation or deletion, and type 2, the result 
of a missense mutation, based on adrenal 
involvement and risk of pheochromocytoma, 
in which type 2 carries risk of 
pheochromocytoma and type 1 does not  (3, 
4). Type 1 typically carries high risk for renal 
involvement, high risk for CNS 
hemangioblastomas, and low risk for the 
development of pheochromocytomas (1). 
Type 2 VHLS is further divided into A, B, and 
C based on the predisposition for renal 
involvement, classified as low risk, high 
risk, and no risk, respectively (3, 4).  Type 
2A typically carries low risk for renal 
involvement and high risk for the 
development of both hemangioblastomas of 
the CNS and pheochromocytomas. Type 2B 
typically carries high risk for renal 
involvement, CNS hemangioblastomas, and 
pheochromocytomas. Type 2C typically 
carries very low risk for renal involvement, 
low risk for CNS hemangioblastomas and 
high risk for pheochromocytomas (1). This 
review will discuss the implications of renal 
involvement in VHLS and therefore only 
include VHLS type 1, type 2A, and type 2B. 
 
Materials and Methods 
 
A comprehensive literature review was 
conducted for articles published between 
1990 and 2015 using PubMed with regard 
to genetic and molecular mechanisms of vhl 
and the clinical and pathological diagnosis, 
treatments, and prognosis of renal tumors 
in this disease. Data for this review was 
acquired using combinations of the 
following terms: von Hippel-Lindau 
syndrome, von Hippel-Lindau disease, von 
Hippel-Lindau, renal cell carcinoma, 
radiology, screening, treatment, 
nephrectomy, VHL, VHL gene, HIF, 
metastatic, nephron sparing surgery, 
ablation. We excluded articles not written in 
English and any study that excluded 
hereditary cancer syndromes from its 
inclusion criteria, which resulted in the 
exclusion of approximately 10 peer-reviewed 
articles each. After assessing the available 
literature, 81 peer-reviewed articles and 
their sources met our inclusion criteria and 
were included in this review. 
 
Genetics of vhl and Molecular 
Mechanisms of VHL protein 
 
The vhl gene is located at chromosome 
3p25-p26, and contains 3 exons; over 300 
germ-line mutations have been described 
leading to VHLS (1, 2). The vhl gene is also 
conserved across many taxa of living 
organisms and thus is considered to be 
fundamental to life (5). Several studies have 
implicated the role of vhl as a tumor 
suppressor gene and mutations of the wild-
type and loss of heterozygosity are thought 
to play a major role in tumorigenesis (6). 
 
The protein product of vhl, (pVHL), plays a 
major role in the ubiquitination of multiple 
proteins involved in many cellular pathways 
and contains binding domains for elongin C, 
elongin B, and cullin-2 (7-9). The resulting 
multimeric protein complex is known as the 
VHLcomplex (7). Often mutations in vhl 
affect the expression of pVHL, but some 
missense mutations can affect pVHL and 
elongin C binding (10). The role of hypoxia 
induced factor (HIF), a helix-loop-helix 
transcription factor that plays a major role 
in the cellular response mechanism to 
hypoxia, in the VHL pathway has been well-
documented (11-14). The functional, 
dimeric form of HIF is comprised of 2 
subunits, an HIFα subunit (either HIF1α, 
HIF2α, or HIF3α) and an HIF1β subunit (15, 
16). HIFβ is constitutively expressed in 
contrast to HIFα, whose expression is tightly 
regulated via ubiquitination by the VHL 
complex and proteasomal degradation (9). 
Under normoxic conditions the VHL 
complex recognizes HIFα, which is 
polyubiquinated and degraded, thus 
reducing cytoplasmic HIFα (17). This 
recognition of HIFα for ubiquitination by 
VHL complex requires hydroxylation of 
proline residues on HIFα subunits by prolyl 
hydroxylase enzymes (PHD1, PHD2, PHD3), 
which require oxygen as a cofactor (7, 8, 18, 
19). Thus, hydroxylation of HIFα proline 
residues and subsequent ubiquitination 
occurs only in the presence of oxygen (20). 
Under hypoxic conditions, hydroxylation of 
HIFα prolines does not proceed, preventing 
or reducing the VHL complex recognition of 
HIF for ubiquitination, leading to the 
accumulation of HIFα, making it available to 
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bind constitutively expressed HIFβ (21, 22). 
This new HIFαβ complex passes into the 
nucleus and binds to sequences known as 
hypoxia response elements that regulate of 
over 800 hypoxia inducible genes (23). 
Under normal conditions, expression of 
these hypoxia inducible genes allows a 
normal cellular adaptive response to 
hypoxia; however the aberrant regulation of 
many of these genes plays a major role in 
tumorigenesis and angiogenesis. The role in 
tumorigenesis of these genes varies. Several 
hypoxia inducible genes such as vascular 
endothelial growth factor (VEGF), 
erythropoietin, and platelet-derived growth 
factor (PDGF) have been found to have roles 
in angiogenesis (21, 24). Other targets of the 
pVHL-HIF pathway include glucose uptake 
via glucose transporter 1 (GLUT1), 
extracellular matrix remodeling via E-
cadherin and matrix metalloproteinases 
(MMPs), microtubule stabilization via 
modulation of the primary cilium, regulation 
of apoptosis via p53, cell proliferation via 
transforming growth factor-α (TGFα) and 
epidermal growth factor (EGFR), and cell 
cycle progression via cyclin D1 (25-31). More 
recent studies have elucidated the role of 
mutations in other genes coding for proteins 
involved in the VHL-HIF pathway, such as 
TECB1 coding elongin C, resulting in similar 
aberrancies in the pVHL-mediated 
regulation of HIF and downstream induction 
of hypoxia inducible genes (32). 
 
Several studies have also elucidated other 
roles of pVHL in HIF-independent pathways 
involved in tumorigenesis including the 
modulation of extracellular matrix 
components such as fibronectin, collagen 
IV, and integrins (33-35) Furthermore, 
pVHL has been found to be involved in the 
non-HIF-mediated stabilization of 
microtubules through a pVHL binding 
protein (VBP-1) by impacting the assembly 
of microtubule subunits (11, 18, 36).  
 
Renal Pathology and VHLS  
 
VHLS is the most common cause of 
hereditary renal cell carcinoma (RCC), 
specifically clear cell renal carcinoma 
(ccRCC) (37). Prior to the use of computed 
tomography (CT) in regular surveillance of 
VHLS, metastatic ccRCC was thought to be 
the leading cause of death in VHL patients 
(38). VHLS-associated RCC comprises about 
4% of the total RCC incidence and is equal 
in both males and females (5, 39). While 
renal cysts are estimated to occur in up to 
63% of patients with VHLS, renal tumors are 
estimated to occur in 25-45% of patients 
with VHLS and have a mean age at 
presentation of 39 years (5, 37). It should be 
noted that even cases of sporadic, non-
familial ccRCC involve mutations or 
methylation of vhl in up to 91% of cases (40). 
Renal tumors less than 3 cm tend to be less 
invasive with lower pathological T stage; 
however these tumors tend to become more 
aggressive as they increase in size (41). 
Growth rates of renal tumors vary from 0.2 
cm/year to 2.2 cm/year with a mean of 1.6 
cm/year and a mean volume doubling time 
of approximately 26 months (42, 43). 
Metastasis is rare in tumors under 3 cm and 
tumor size on CT has been shown to be a 
prognostic indicator of overall survival (5, 
41). 
 
Renal involvement in VHLS is typically 
characterized by multiple, bilateral, 
recurring cysts or tumors (37, 38). Previous 
studies identified an average of 
approximately 7 renal cysts and 3 renal 
tumors per kidney, however it is 
hypothesized that the number of 
microscopic foci of malignant and non-
malignant neoplasms could be in the 
hundreds and thousands, respectively (44, 
45). 
 
Renal cysts can be classified as simple or 
complex, depending on the presence and 
pattern of septation. The Bosniak 
classification scale is useful in describing 
radiologic findings in VHLS, but due to the 
high potential for malignancy of VHL cysts, 
its prognostic use in management is limited 
(39). Simple sporadic renal cysts have a very 
low rate of malignancy under the classic 
Bosniak classification system, whereas in 
VHLS simple cysts often already contain 
malignant characteristics in their walls (45). 
For this reason, it is recommended to 
undergo screening and active surveillance 
every 6 to 12 months depending on the rate 
of tumor growth and the patient specific 
history of malignancy (46). 
 
Radiology of renal masses in VHL 
 
Renal masses in VHLS often present as 
cystic masses on CT with varying degrees of 
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complexity and septa. Classically, the 
Bosniak classification scale provides a 
method of assessing the malignant potential 
of a renal cyst based on the radiologic 
characteristics of the cyst and provides 
diagnostic indications for management (47). 
It was initially described in the context of 
CT, but can also be used for MRI and has 
also been applied to ultrasound (47, 48). As 
stated above, it is important to note that 
recommendations for management of renal 
cysts cannot be made based on the Bosniak 
classification due to the fact that VHL renal 
cysts tend to have foci of cellular malignancy 
in their walls (46). For this reason, even 
simple cysts are likely to contain some 
malignancy and require active surveillance.  
The Bosniak system is useful in stratifying 
the variation of presentations of renal 
lesions in VHLS, but management decisions 
should be based on the consistency of the 
lesion and size of the largest mass (41). Even 
larger masses, such as a category III, may 
necessitate active surveillance instead of 
treatment based on the consistency of the 
lesion and number of surgeries in the 
patient’s history (39). The use of ultrasound 
has proven useful in the surveillance of 
lesions and identifying their consistency, 
however, this technique lacks uniformity 
and is user dependent. CT and MRI are the 
most useful imaging modalities for the 
surveillance of renal lesions of VHLS (39). 
 
The feasibility and safety of regular CT scan 
in patients with VHLS has come into 
question considering that MRI is a better 
modality for monitoring and identifying 
several non-renal tumors common to VHLS 
and that high levels of radiation exposure 
can occur with regular CT (46). Several 
studies suggest the use of regular MRI in 
surveillance of VHL lesions; however these 
advantages are not without risk (49, 50). 
The possibility of nephrogenic systemic 
fibrosis secondary to the use of gadolinium 
contrast in patients with compromised renal 
function and cost should be considered in 
surveillance strategy (50). For this reason, it 
is important to consider each patient on a 
case-by-case basis, but active surveillance 
has been well established as a key aspect of 
the management of VHLS (39). 
 
Treatment of renal masses in VHLS 
 
Over the past few decades, nephron-sparing  
surgery (NSS), either open partial 
nephrectomy (PN) or enucleation, has 
become the standard surgical intervention 
for managing RCC in VHLS (51-53). Prior to 
NSS, the major approach was bilateral 
radical nephrectomy, leaving patients 
dependent on transplantation or dialysis, 
with high mortality rate and low quality of 
life (54). In 1995, Steinbach et al (54) found 
cancer-specific survival (CSS) rates at 5 and 
10 years of 100 and 81 percent for patients 
undergoing NSS, compared to the CSS rates 
at 5 and 10 years of 73 and 36 percent for 
patients undergoing radical nephrectomy. 
Since then other studies have identified NSS 
as a superior approach for most cases (55, 
56). The goal of NSS is to maximize 
remaining functional renal parenchyma 
(56). Since smaller renal tumors are 
typically considered low stage and low grade 
with low metastatic potential, PN is usually 
reserved for tumors greater than 3 cm, at 
which metastatic potential drastically 
increases, however some centers prefer a 4 
cm cutoff (42, 57). The de novo recurrence 
rate of RCC in VHL is up to 85% at 10 years 
and the need for multiple NSSs will arise in 
many patients (54). It should be noted that 
in 2007, Ploussard et al (58) found a cancer-
specific survival of 93.8% in a 24 VHL 
patient cohort in which 63.4% of patients 
required repeat NSS. A more recent study in 
2012 by Singer et al (55) found a cancer 
specific survival at 10 years of 97% in 128 
patients who underwent at least bilateral 
NSS, of which 70% had VHL and 68% of 
patients required repeat ipsilateral NSS. In 
2012, Jilg et al (57) also found repeat NSS 
to be practical, establishing a limit of up to 
three repeated NSSs with complication rates 
of 53.6% for the first NSS, 33.3% for the 
second NSS, and 67% for the third NSS with 
a high proportion of more severe 
complications after the third NSS. 
Furthermore, NSS has been proven to be 
superior to bilateral radical nephrectomy 
and renal replacement therapy in overall 
survival, cancer-specific survival and 
morbidity and mortality in the management 
of VHLS (55). However, this study and other 
studies highlight the technical skill 
requirement and difficulty of repeat NSS (55, 
59, 60). The number of repeated surgeries is 
limited by post-operative fibrosis and the 
increased morbidity and mortality 
associated with each surgery (53, 56, 61). 
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The recurrent nature of this disease obviates 
the need for a less invasive second-line 
therapy (60). Percutaneous ablation, 
including radiofrequency ablation and 
cryoablation, has proven to be a major 
candidate in both early and later stages of 
management of smaller renal tumors in 
VHLS (61-65). Percutaneous ablation is 
typically reserved for tumors between 2-3 
cm and as a secondary procedure in most 
cases (42, 65). In 2010, Park et al. (66) found 
that radiofrequency ablation successfully 
managed 88% of renal masses in 11 patients 
with recurring tumors secondary to VHLS. 
In 2013, Yang et al (67) found cryoablation 
to have a failure rate of 7.7% in patients with 
VHLS compared to a failure rate of 21.4% for 
radiofrequency ablation. They also found 
both radiofrequency ablation and 
cryoablation to have 100% 5-year CSS (67). 
Although recurrence rates are higher than 
NSS, ablation carries lower incidence of 
morbidity and mortality (66). However, there 
are several contraindications to ablation 
including cystic tumors, tumors adjacent to 
critical structures (e.g. ureter and bowel) 
and extensively multifocal tumors, all of 
which are common in VHLS (60). 
 
Several surgical interventions are available 
for the management of RCC in VHLS and 
weighing oncologic outcomes against 
operative morbidity and mortality is crucial 
in VHL management decisions (60). 
However, trends in preserving functional 
renal parenchyma in patients with VHL have 
improved survival outcomes over the past 
few decades (56). Pre-operative management 
and surveillance of other malignancies must 
also be considered, as these can cause 
major intraoperative complications, such as 
hemorrhage of a hemangioblastoma or 
pheochromocytoma disrupting patient 
intraoperative stability (53). It is important 
to keep in mind that these patients are not 
only subject to RCC but also multifaceted 
systemic malignant neoplasms, the 
treatment of which can have high morbidity 
and severely decrease quality of life (53). 
Maximizing efforts to use minimally invasive 
techniques should be a major consideration 
of future management. 
 
Targeted therapy in RCC and VHL 
 
Advancements in understanding vhl and the 
activity of pVHL have provided key insight 
into potential mechanisms of therapeutic 
intervention in ccRCC and systemic 
treatment for VHL using targeted therapies 
(68). Few studies have been conducted on 
the efficacy of these drugs specifically in the 
context of VHSL, however, extensive 
research has been conducted on metastatic 
ccRCC. Considering most ccRCC involves 
aberrancies in vhl, these studies are 
expected to translate (40). 
 
Older targeted therapies involved 
immunomodulation through cytokines IFN-
α and IL-2, and had low relative risk 
reduction. IFN-α proved to have little 
therapeutic value and caused flu-like 
symptoms, fatigue, and depression; 
however, it is still seen in some trials as a 
point of reference (69). IL-2 showed benefit 
in some patients for long-term use and is 
still recommended in few select cases, 
however the adverse events of IL-2 have 
limited its use in current practice (70). 
These more classic immunotherapies have 
given way to newer targeted therapies 
involving the VEGF and mammalian target 
of rapamycin (mTOR) pathways that have 
since been approved by the Food and Drug 
Administration (FDA). 
 
As noted previously, the loss of functional 
pVHL results in downstream over-
expression of VEGF (21). Several oral 
tyrosine kinase inhibitors (TKI), sunitinib, 
sorafenib, pazopanib, and axitinib, and one 
monoclonal antibody, bevacizumab, 
decrease VEGF and PDGF signaling thereby 
decreasing angiogenesis and disrupting 
tumorigenesis (71). In 2009, Motzer et al 
(72) found a significantly improved overall 
survival and progression free survival (PFS) 
using Sunitinib as a first-line treatment in 
patients with metastatic ccRCC. Another 
study by Jonasch et al (73) found a 33% 
partial regression of RCC in a cohort of 18 
patients with VHLS (p=0.014). Sorafenib, a 
TKI similar to sunitinib, as first-line 
treatment has also been proven to improve 
PFS in metastatic ccRCC, however, both 
sunitinib and sorafenib have similar adverse 
event profiles including diarrhea, rash, 
fatigue, and hand-foot syndrome (72, 74). 
Early trials with pazopanib found a 
significantly increased PFS with a better 
adverse event profile than other TKI anti-
angiogenics, however more recent trials 
have shown no significant increase in 
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overall survival over placebo (75, 76). 
Bevacizumab, a humanized monoclonal 
antibody for VEGF-α, has shown increased 
PFS in second-line use with IFN-α (77). 
Many other TKIs are under investigation for 
use in ccRCC, but have not yet been 
approved by the FDA (71). 
 
Furthermore, the FDA has approved two 
agents, temsirolimus and everolimus, for 
ccRCC that involve the disruption of the 
PI3K/AKT/mTOR pathway. Temsirolimus, 
an inhibitor of mTORC1, is an intravenous 
agent that has shown significantly improved 
survival and can be used among high-risk 
patients (78, 79). Everolimus, an oral mTOR 
directed therapy, has been approved for 
second-line use in metastatic ccRCC, 
showing improved PFS, but no overall 
survival improvement (80, 81). Both of these 
agents have a similar adverse event profile 
of rash, mucositis, interstitial pneumonitis, 
hyperglycemia, and hyperlipidemia (78, 80). 
 
Conclusion 
 
In conclusion, VHLS is a multifocal, 
hereditary neoplastic disorder that 
necessitates a complex multidisciplinary 
approach in its management (53). The 
protein product of vhl, known as pVHL, 
forms a multimeric complex with other 
intracellular proteins to form a molecule 
capable of ubiquitinating and degrading HIF 
proteins, preventing the over-expression of 
hypoxia inducible genes. Aberrant VHL 
contributes to angiogenesis and 
tumorigenesis and is implicated in both 
sporadic and VHLS-associated ccRCC (7-
32). Tumors can be cystic or solid in nature 
and a cutoff of typically 3 cm, but sometimes 
4 cm, is used to indicate the necessity for 
surgical management (42, 57). Radiologic 
surveillance can be done via several 
modalities including ultrasound, MRI, and 
most often CT, however each modality has 
its own advantages and disadvantages (39). 
NSS is the preferred surgical approach for 
renal tumors in VHL, typically using open 
PN for earlier, larger masses and 
percutaneous ablation for later, smaller 
tumors (55, 66). Systemic therapy, involving 
TKIs of the VEGF pathway and mTOR 
inhibitors, has been shown to improve CSS 
in metastatic ccRCC and in the rare studies 
available on VHL only cohorts (71-81). The 
multifocal nature of VHL mandates   
complex multidisciplinary management 
strategies that require special 
considerations (53). 
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